SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " Medicines " 120 found 🔀 AI-powered Shuffle
Hims & Hers Health and Novo Nordisk End Lawsuit Over Weight Loss Medications, Enter Collaboration
Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see Novo Nordisk’s branded weight loss medicines sold through the Hims platform. Shares of Hims & Hers Health Inc. jumped more than 40% in ...
FDA’s controversial vaccine chief will exit agency next month
The US Food and Drug Administration’s head of vaccines and biologic medicines will leave the agency at the end of April, a spokesperson confirmed to CNN on Friday.
European health agency recommends approving Moderna’s combined flu, COVID vaccine
The European Medicines Agency (EMA) announced Friday it has recommended Moderna’s combined mRNA COVID-19 and flu vaccine be granted market authorization in the European Union, marking the fir…
Scientists turn methane into medicine in stunning breakthrough
Scientists have unveiled a breakthrough way to turn natural gas—long burned as fuel—into valuable chemical building blocks for medicines and other high-demand products. By designing a clever iron-based catalyst powered by LED light, researchers managed to activate stubborn molecules like methane and transform them into complex compounds, even creating the hormone therapy drug dimestrol directly from methane for the first time.
AbbVie to invest $380 million to expand US manufacturing in Illinois
AbbVie on Monday said it would invest $380 million to build two new active pharmaceutical ingredient manufacturing facilities at its Illinois campus, expanding its domestic production capacity for its neuroscience and obesity medicines.
Girding against Keytruda cliff, Merck splits oncology into standalone business unit
The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. | The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming medicines by splitting its core pharmaceutical business in two.
Merck to create separate cancer business to offset Keytruda patent loss
Merck said on Monday it will split its human-health business into two divisions, separating its cancer franchise from its non-oncology medicines.
Ultrafast quantum chemistry engine could speed up the development of new medicines and materials
The powerful software can reduce the time needed to simulate reactions with large molecules from weeks to just minutes.
Studies test whether gene-editing can fix high cholesterol
Millions take cholesterol-lowering medicines such as statins, the cornerstone of treatment.
TrumpRx, the President’s Online Drugstore, Opens for Business
TrumpRx is aimed at helping patients use their own money to buy medicines. But researchers who study drug pricing warned that many patients could pay too much if they use the site.
Science & Medicine: Studying the chemical miscommunication that may lead to obesity
The chemical cross-communication between the guts and other organs that occurs when a person metabolizes nutrients begins before we open our mouths, when we see or smell food. The answer to why some people develop obesity, diabetes, and other metabolic disorders, and why some people respond so well to medicines like Ozempic, might lie in those signals. UT Health San Antonio endocrinologist Dr. Marzieh Salehi is studying that communication in patients with spinal cord injury.
How scientists are turning thyme into precision medicine
Thyme extract is packed with health-promoting compounds, but it is difficult to control and easy to waste. Researchers created a new technique that traps tiny amounts of the extract inside microscopic capsules, preventing evaporation and irritation. The method delivers consistent nanodoses and could eventually be used in medicines or food products. It may also work for many other natural extracts.
BeOne CEO on Business Strategy, Biotech Outlook
John Oyler, Co-founder, Chairman and CEO at BeOne Medicines, discusses the company's business strategy and the outlook for the biotech sector. He speaks with Avril Hong and Paul Allen from the sidelines of the JPMorgan Healthcare Conference in San Francisco. (Source: Bloomberg)
Fact check: Trump’s Detroit economic speech
Inflation hasn’t “stopped.” Consumer prices are up during this presidential term, not “down.” Grocery prices are rising, not starting to fall “rapidly.” US businesses and consumers, not China, pay US tariffs on Chinese imports. It’s impossible to reduce prescription drug prices by “thousands” of percentage points, since this would mean Americans would be getting paid to acquire their medicines.
JPM26: Bristol Myers CEO to ‘cast a broad net’ as business development remains a top priority
San Francisco—Bristol Myers Squibb is already aiming to launch more than 10 new medicines by 2030. | Bristol Myers Squibb is already aiming to launch more than 10 new medicines by 2030. But to hear CEO Chris Boerner, Ph.D., tell it, “business development remains a top priority” for the company’s capital allocation strategy heading into 2026.
An AI revolution in drugmaking is under way
It will transform how medicines are made—and the industry itself
Should the NHS really use magic mushrooms to treat mental health?
Many clinical trials to test the use of psychedelic medicines for conditions such as depression have been underway since 2022 - with surprising results
enGene Reports Full Year 2025 Financial Results and Provides Business Update
BOSTON & MONTREAL, December 22, 2025--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the full year ended October 31, 2025, and provided a business update.
‘A potential treasure trove’: World Health Organization to explore benefits of traditional medicines
UN body to study possibility of integrating centuries-old practices into mainstream healthcare
WHO issues global guideline on the use of GLP-1 medicines in treating obesity
To address the growing global health challenge of obesity, which affects more than 1 billion people, WHO has released its first guideline on the use of Glucagon-Like Peptide-1 (GLP-1) therapies for treating obesity as a chronic, relapsing disease.